Late breaking abstract submissons now open until November 21st, 2024

ABSTRACT SUBMISSION INSTRUCTIONS

deadline: Thursday November 21st, 2024 at 11:59 pm ET

This year we are in-person program for HIV & Respi-DART 2024. You can use this link to submit an abstract for the HIV DART track or for the RespiDART track. If you are submitting more than one abstract, please fill out and submit a new form each time. Upon receiving your submission, your abstract will be reviewed by the Scientific Committee and if accepted, you will be invited to present your abstract in-person on December 2 or 4th, 2024. 
 

Guidelines

  • Use Arial font size 11 for your abstract

  • Please include a title in bold at the top of the abstract, this should be followed by list of authors and affiliations

  • All submitted abstracts should consist of background, methods, results, and conclusions  

  • All text should flush to the left side of the page

  • Although there is no word limit to the abstract, we recommend a length of 500 words

  • If you choose to include figures, tables, or chemical structures in your abstract, please fit the abstract to one page (A4)

  • It is a requirement of participation in DART series conferences that all chemical structures be disclosed for investigational compounds that are presented at the virtual meeting, including oral abstracts, poster presentations, and invited speaker talks.

Please see below for an example of an abstract:

Categories for abstract submission: 

For HIV-DART Track:

  • Aging and HIV

  • Animal models

  • Anti-HIV therapeutics and long-acting slow-release formulations

  • Clinical trials

  • Co-infections

  • Co-morbidities

  • Diagnostics

  • Drug resistance

  • Epidemiology and transmission

  • HIV cure

  • HIV drug development

  • Other HIV related submissions

  • Other: ______

For Respi-DART Track:

  • Long COVID

  • COVID-19

  • Public health and global response to emerging viruses

  • Antiviral drug development: Pre-clinical small molecule inhibitors 

  • Antiviral drugs in clinical development 

  • Host-directed therapies 

  • Pre-clinical and clinical drug development for emerging viruses 

  • Immunology and vaccine development

  • Diagnostics

  • Drug resistance, vaccine resistance, and viral evolution

  • Biochemistry, host-virus interactions and virus replication

  • Novel assay and animal model development

  • Special considerations for pediatrics populations

  • Systemic pathogenesis of respiratory viruses (outside the respiratory virus system)

  • Non-respiratory emerging viruses

  • Emerging viruses including Yellow Fever, Dengue, Chikungunya, Noro, Zika, Nipah, and more.

  • Other: ______

Abstract publication 

All accepted abstracts will be published in the electronic abstract book made available on November 29, 2024 at 4pm ET.